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ABSTRACT
Glycoprotein B (gB), the fusogen of herpes simplex virus (HSV), is a class III fusion protein with a trimeric ectodomain of known
structure for the postfusion state. Seen by negative-staining electronmicroscopy, it presents as a rod with three lobes (base, mid-
dle, and crown). gB has four functional regions (FR), defined by the physical location of epitopes recognized by anti-gB neutral-
izing monoclonal antibodies (MAbs). Located in the base, FR1 contains two internal fusion loops (FLs) and is the site of gB-lipid
interaction (the fusion domain). Many of the MAbs to FR1 are neutralizing, block cell-cell fusion, and prevent the association of
gB with lipid, suggesting that these MAbs affect FL function. Here we characterize FR1 epitopes by using electronmicroscopy to
visualize purified Fab-gB ectodomain complexes, thus confirming the locations of several epitopes and localizing those of MAbs
DL16 and SS63. We also generatedMAb-resistant viruses in order to localize the SS55 epitope precisely. Because none of the
epitopes of our anti-FR1MAbsmapped to the FLs, we hyperimmunized rabbits with FL1 or FL2 peptides to generate polyclonal
antibodies (PAbs). While the anti-FL1 PAb failed to bind gB, the anti-FL2 PAb had neutralizing activity, implying that the FLs
become exposed during virus entry. Unexpectedly, the anti-FL2 PAb (and the anti-FR1MAbs) bound to liposome-associated gB,
suggesting that their epitopes are accessible even when the FLs engage lipid. These studies provide possible mechanisms of action
for HSV neutralization and insight into how gB FR1 contributes to viral fusion.
IMPORTANCE
For herpesviruses, such as HSV, entry into a target cell involves transfer of the capsid-encased genome of the virus to the target
cell after fusion of the lipid envelope of the virus with a lipid membrane of the host. Virus-encoded glycoproteins in the envelope
are responsible for fusion. Antibodies to these glycoproteins are important biological tools, providing a way of examining how
fusion works. Here we used electronmicroscopy and other techniques to study a panel of anti-gB antibodies. Some, with virus-
neutralizing activity, impair gB-lipid association. We also generated a peptide antibody against one of the gB fusion loops; its
properties provide insight into the way the fusion loops function as gB transits from its prefusion form to an active fusogen.
Herpes simplex virus (HSV) has four envelope glycoproteinsthat are essential for virus entry into cells: glycoproteins gD,
gH, gL, and gB. All herpesviruses use a combination of gB and the
heterodimer gH/gL to carry out virus-cell fusion, with current
evidence indicating that gB is the fusion protein (1–4). Like most
alphaherpesviruses, HSV also requires the receptor-binding pro-
tein gD to carry out fusion. Our current model of HSV fusion
starts with the binding of gD to one of its receptors (nectin-1,
herpesvirus entry mediator [HVEM], or 3-O-sulfotransferase [3-
OST] heparan sulfate) (5), transmitting a physical signal to gH/gL,
which, in turn, acts upon gB to trigger fusion (2).
HSV-1 gB (gB1) is a 904-amino-acid (aa) type I membrane
glycoprotein whose crystal structure identifies it as a class III fu-
sion protein (1, 6). The gB1 ectodomain comprises residues 31 to
773, and several crystal structures have been determined for resi-
dues 103 to 725, all of them in the postfusion form. These struc-
tures show a homotrimer with a long central coiled-coil and in-
ternal bipartite fusion loops (fusion loops 1 and 2 [FL1 and FL2])
(Fig. 1A). A similar crystal structure has been observed for gB from
the betaherpesvirus Epstein-Barr virus (EBV) (7). In the absence
of sequence similarity, EBV gB and HSV-1 gB share a high degree
of structural similarity with other class III fusion proteins, includ-
ing vesicular stomatitis virus (VSV) glycoprotein G (8) and bacu-
lovirus gp64 (9).
The atomic structure of postfusion gB shows a subunit with
five structural domains (domains I to V), four of which are similar
to those of other class III fusion proteins (1, 7–9). Visualized at a
lower resolution by electron microscopy (EM), the trimer appears
as a rod with three distinguishable lobes (6, 10–13), to which we
refer as the base, middle, and crown. Additionally, we mapped the
epitopes of a panel of neutralizing monoclonal antibodies (MAbs)
to distinct regions of the gB structure, thereby defining four func-
tional regions (FR) (14). According to this mapping, FR1 includes
structural domains I and V and forms the base of the gB trimer
(Fig. 1B). Structural domain I contains the fusion loops (FLs) and
is referred to as the fusion domain. Mutations within the FLs block
virus entry and egress, as well as cell-cell fusion and virus spread
(15–18). Certain MAbs with epitopes in FR1 also block gB-cell
binding (19), gB-liposome binding (16), and gB-gH/gL associa-
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tion (20, 21). Importantly, cryo-EM studies show that gB binds to
liposomes via the fusion loops of FR1 (13). Taken together, exist-
ing data suggest that FR1 is directly involved in gB-lipid associa-
tion during virus-cell and cell-cell fusion.
FR2 maps to structural domain II and is located in the middle
lobe of gB (Fig. 1B). Because MAbs to this FR block gB-gH/gL
association (20), we hypothesize that FR2 is the site of at least one
gB-gH/gL interaction. FR3 overlaps structural domain IV and is
located at the crown of gB. Certain MAbs that map to this FR block
gB-cell binding (19), suggesting that a potential gB receptor binds
to this region (16). Mutations that affect the rate of fusion also
map to FR3 (17). Finally, FR4 (residues 31 to 86) corresponds to
the N terminus of gB (22–25), for which the crystal structure has
not yet been solved (1, 6). MAbs within each FR have been further
subdivided into groups based on peptide and gB truncation map-
ping and their abilities to compete with other MAbs for binding to
gB (Fig. 1C) (14).
Our data show that the two FLs within FR1 constitute a “sub-
domain” wherein key hydrophobic amino acids form a ridge that
is supported on both sides by charged residues. It is hypothesized
that the hydrophobic residues interact with target membranes
(13, 15, 16), helping gB to form the fusion pore. Soluble gB pro-
teins, which are in a postfusion form, have an intrinsic ability to
associate with target membranes via their fusion domains; amino
acid substitutions in either FL abrogate this association (16). In
the prefusion forms of most class I and class II viral fusion pro-
teins, the fusion peptides/loops are buried (26). Although the pre-
fusion form of gB has not been solved, we postulate that the hy-
drophobic membrane-proximal region (MPR) (residues 731 to
773) masks the FLs, since the presence of the MPR reduces the
capacity of the gB ectodomain trimer to bind liposomes (27).
As yet, we do not know how FR1 works to direct the FLs and,
consequently, to promote the process of membrane fusion. Anti-
bodies (Abs) provide an indirect way of examining this region.
How do MAbs with epitopes in FR1 neutralize the virus and im-
pair cell-cell fusion? Furthermore, what does information of this
kind say about how gB works to achieve fusion? In order to answer
these questions, we need to first define the epitopes of these MAbs.
FIG 1 (A) Surface representation of the crystal structure of the HSV-1 gB trimer. One monomer is colored according to the structural domain designations (I
to V) given by Heldwein et al. (1), while the other two are in gray. An enlarged view of the gB base, highlighting the three pairs of FLs (colored pink for FL1 and
cyan for FL2), is also shown. (B) Ribbon representation of one gB monomer labeled with the locations of relevant FR and domains, colored as in panel A. (C) HSV
gB MAb “tree” showing the relationships between the different antibodies. The anti-gB MAbs are arranged by FR. Group names are given according to structural
domain (from Bender et al. [14]) and are colored as shown in panel B. Arrows between groups denote binding competition among MAbs. Amino acid residues
for known epitopes (determined through peptide analysis, truncation mutants, or mar mutant viruses) are shown. The antibodies studied in this paper are listed
in boldface. MAb SS63, which was originally assigned to group 5b (FR1) (14), has been reclassified to group 4c (FR3) on the basis of the findings presented in this
report.
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From our panel of anti-gB FR1 MAbs (14), we selected SS55,
which mapped to domains I and II, and SS144 and SS63, which
mapped to domain V, for further study.
We examined Fab-gB complexes by EM, choosing them from
each FR in addition to SS55, SS144, and SS63. We also included
MAb DL16, which does not neutralize virus but is trimer specific
(14). These data show that SS55 binds to the base of gB (FR1), a
finding that, combined with previous results, assigns its epitope to
domain I. This epitope was further narrowed by generating and
sequencing MAb-resistant (mar) mutants. The EM data also con-
firmed the positioning of SS144 at the base of gB (14). Interest-
ingly, the Fabs for both SS55 and SS144 neutralized virus and
impaired liposome binding in vitro, suggesting that these activities
are intrinsic to the MAbs as they engage their epitopes and are not
due to IgG cross-linking. Finally, EM results positioned the
epitope of DL16 within the base of gB and that of SS63 within the
crown (FR3).
Because none of the anti-FR1 MAbs mapped directly to the
FLs, we next generated polyclonal antibodies (PAbs) against pep-
tides spanning either FL1 or FL2. While the anti-FL1 PAb failed to
bind gB, the anti-FL2 PAb bound gB and neutralized virus, indi-
cating that portions of the FLs are accessible to antibody either in
prefusion gB or as an intermediate that forms as gB moves from its
prefusion to its postfusion conformation. Presently, all of our
structural data are derived from postfusion gB; anti-FR1 antibod-
ies, such as anti-FL2, may help us dissect the dynamics of the
fusion process at earlier time points.
MATERIALS AND METHODS
Cells and soluble proteins. African green monkey kidney (Vero) cells
were grown in Dulbecco’s modified Eagle medium (DMEM) with 5%
fetal bovine serum (FBS). 293T cells were grown in DMEM containing
10% FBS. Soluble gB1(730t) (gB1 truncated at aa 730), gB2(727t), and
gB1(773t) were purified from baculovirus-infected insect (Sf9) cells by
use of a DL16 immunosorbent column as described previously (27–29).
Antibodies. Rabbit PAbs R238 and R239 were generated against a
20-amino-acid gB peptide (residues 167 to 186) corresponding to FL1 and
its surrounding amino acids. Likewise, PAbs R240 and R241 were gener-
ated against a gB peptide encompassing FL2 (residues 252 to 271). Since
antibodies from each pair of rabbits behaved identically, data from only
one rabbit are shown in the results; these PAbs are referred to as anti-FL1
or anti-FL2 for ease of presentation. Rabbit PAb R242 was generated
against a protein corresponding to the cytoplasmic tail of gB (residues 801
to 904) (30), a gift from E. E. Heldwein. Anti-peptide PAbs were made as
described previously (31). gB-specific MAbs C226, DL16, SS10, SS55,
SS63, and SS144 have been characterized previously (14, 19). To prepare
Fabs for EM, IgGs were digested by immobilized papain (Thermo Scien-
tific) overnight at 37°C. Papain-agarose beads were removed by centrifu-
gation, and the supernatant was passed over a protein A column (GE
Healthcare). The protein A flowthrough (containing Fab fragments) was
collected and dialyzed against phosphate-buffered saline (PBS), and SDS-
PAGE was run, followed by Coomassie staining, for verification of Fab
isolation.
Transmission electron microscopy and image analysis. To prepare
gB-Fab complexes, 300g SS10 Fab was incubated with 100g gB1(730t)
in a 250-l total volume (PBS) at room temperature (RT) for 1 h. The
complex was then filtered through a 0.22-m Spin-X filter (Corning) and
was loaded onto a Superdex 200 column (Äkta purifier system) at 0.2
ml/min. The gB-Fab complex eluted from the column at fractions 13 to 15
(0.5 ml per fraction). Purified gB-Fab samples (15 g/ml) were adsorbed
onto grids bearing a carbon-coated support film, negatively stained with
2% uranyl acetate, and imaged with a CM120 transmission electron mi-
croscope (FEI, Hillsboro, OR) using a 1,024- by 1,024-pixel charge-cou-
pled device (CCD) camera (Gatan, Warrendale, PA). The nominal mag-
nification was 60,000 (0.33 nm/pixel). EMAN2 (32) was then used to
align, classify, and average the gB or gB/Fab particles using an iterative
multivariate statistical analysis reference-free classification algorithm as
implemented in e2refine2d. The number of particles contributing to each
class average ranged from 25 to 60. To confirm that the crown and base
domains could be reliably distinguished, the resulting 2-dimensional
(2D) class averages were compared with model projections calculated
from the crystal structure (Protein Data Bank [PDB] code 3NWF [6]) and
band-limited to 25 Å resolution, using Bsoft (33).
Selection of SS55mar viruses. Monoclonal antibody-resistant (mar)
viruses were generated according to the protocol outlined by Cairns et al.
(34). HSV-2 strain 333 was added to confluent Vero cell monolayers in
6-cm tissue culture dishes (approximately 500 PFU/plate). After 1 h at
37°C, the virus inoculum was removed, and the plates were overlaid with
5 ml DMEM, 5% heat-inactivated FBS, 1 penicillin-streptomycin, 0.5%
carboxymethyl cellulose, and 100 g/ml SS55 IgG. Plates were incubated
at 37°C for 3 to 4 days. Plaques were picked and amplified on Vero cells
and were then subjected to a second round of MAb selection followed by
plaque purification. The final gradient-purified stocks of SS55mar viruses
were able to infect cells in the presence or absence of SS55.
PlasmidDNAs.Plasmids pPEP98 (wild-type [WT] gB) and pCAGGS/
MCS were gifts from P. Spear (35, 36). Plasmids pCW1029 (R335Q) and
pCW1028 (A203T) were generated by PCR amplification of the gB open
reading frame (ORF) from SS55-resistant HSV-1. To prepare the total-
cell infected DNA for cloning, Vero cells (2  105) were seeded into
individual wells of a 24-well plate. The following day, cells were infected at
a multiplicity of infection (MOI) of 1. Cells were recovered after 24 h,
pelleted for 30 s at 13,000 g in a microcentrifuge, and resuspended in 10
mM Tris (pH 7.5). Samples were adjusted to 200 mM Tris (pH 8), 50 mM
EDTA, 0.5% SDS, and 100g/ml proteinase K and were incubated for 1 h
at 65°C. Finally, samples were extracted twice with phenol-chloroform
(24:1), ethanol precipitated, and dissolved in sterile water. This material
was used as the template for PCR (Pfu Ultra) amplification of gB se-
quences using the following primers: 5=-GCGGTACCCGCCATGCACC
AGGGCGCCCCCTCGT (KpnI site underlined; start codon in boldface)
and 5=-CGCTCGAGTGCGCATGCGGTTTAACACCCGTGGTT (XhoI
site underlined). Finally, the PCR-amplified gB ORFs were cloned into
vector pCAGGS/MCS, which had been digested with KpnI and XhoI.
Plasmid pBH805 (D199A) was created using QuikChange XL site-di-
rected mutagenesis (Stratagene Cloning Systems) (37) with pPEP98 as the
template. The gB genes in each plasmid were sequenced (University of
Pennsylvania Cell Center DNA Sequencing Core Facility) to screen out
PCR errors.
Virus neutralization assays. Serial dilutions of antibody (IgG or Fab)
were mixed with HSV-1 (KOS) or HSV-2 (333), and the mixture was
incubated at 37°C for 1 h. Monolayers of Vero cells grown in 48-well plates
were then incubated with the Ab-virus mixture for 24 h. Cells were fixed
with methanol-acetone (2:1), and plaques were visualized by the black
plaque assay (38).
Purification of gB-specific IgGs from total rabbit IgGs. (i) gB immu-
nosorbent column. Briefly, 1.1 g activated CNBr Sepharose 4B (Pharma-
cia) was swollen in 0.001 N HCl at RT for 1 h. The gel was washed with 50
to 100 ml of 0.001 N HCl on a glass filter. Soluble, purified gB2(727t) (10
mg) (29) in 2.8 ml PBS plus 2.8 ml of freshly made 0.1 M carbonate buffer
(0.2 M sodium bicarbonate, 1 M NaCl [pH 8.3]) was mixed with the gel
overnight at 4°C. Next, the mixture was washed with 1 M ethanolamine
(pH 8.0), then with 0.1 M sodium acetate–1 M NaCl (pH 4.0), and finally
with 0.1 M sodium borate–1 M NaCl (pH 8.0), all at RT. The protein-gel
mixture was then equilibrated with TS washing buffer (10 mM Tris-HCl
[pH 7.2], 0.5 M NaCl) at 4°C and was loaded onto a column.
(ii) Selection of gB-specific IgGs through the gB2(727t) column.The
gB2(727t) column was washed extensively with TS buffer before being
loaded with total anti-FL IgGs. The flowthrough was collected and was
recycled through the column 5 times, followed by washing with TS buffer.
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The gB-specific IgGs were eluted with 3 ml of 0.1 M ethanolamine (pH
11.5). The eluted sample was further dialyzed with PBS and was concen-
trated with centrifugal filter units (Millipore).
ELISA. (i) Capture ELISA. Prior to the enzyme-linked immunosor-
bent assay (ELISA), 12-well plates seeded with 293T cells were transfected
with plasmids expressing mutant or WT gB via the GenePORTER proto-
col (Gene Therapy Systems, Inc.). Two days posttransfection, cells were
lysed using 5% NP-40 –PBS and were immediately used for the capture
ELISA approach (39). Each well of a 96-well plate was washed 3 times with
PBS and was then coated with 50 l of PAb R242 (10 g/ml) for 2 h. The
plate was next washed 3 times with blocking buffer (PBS, 0.05% Tween 20,
0.5% bovine serum albumin [BSA]), after which the cell lysates were
added for 1 h. The plate was then blocked with 5% milk-PBS-0.05%
Tween (T) for 30 min, followed by addition of the MAbs to be tested (10
g/ml in 5% milk-PBS-T) for 1 h. gB-MAb binding was detected by in-
cubation with a horseradish peroxidase (HRP)-conjugated goat anti-
mouse antibody for 30 min at a dilution of 1:200 in 5% milk-PBS-T,
followed by the addition of ABTS [2,2=-azinobis(3-ethylbenzthiazoline-
sulfonic acid)] substrate, and the signal was read at 405 nm. For each
antibody, the signal generated from a control well containing no lysate
was subtracted from the final reading.
(ii) Peptide ELISA. After gB column purification, PAbs R240 and
R241 (anti-FL2p) were tested for binding to a series of overlapping pep-
tides corresponding to the gB ectodomain (14). Fifty microliters of each
peptide at 1 M (in PBS) was placed in each well of a 96-well plate. The
wells were washed and were then incubated in blocking buffer. After 30
min at 37°C, 5-fold dilutions of IgG or preimmune sera were added, and
the plates were incubated for an additional 1 h at 37°C. Antibodies were
detected using an HRP-conjugated goat anti-mouse antibody as described
above.
Biosensor/surface plasmon resonance (SPR) experiments. Experi-
ments were performed using a Biacore 3000 or Biacore X100 optical bio-
sensor (GE Healthcare, Biacore Life Sciences) at 25°C. Filtered and de-
gassed HBS-N buffer (10 mM HEPES [pH 7.4], 150 mM NaCl) was used
in all liposome association experiments. We used an L1 sensor chip (Bia-
core) for binding liposomes and followed our previous protocol (27).
Liposomes were purchased from Encapsula NanoSciences (Nashville,
TN) at a size of 400 nm, containing a 1.7:1 molar ratio of soy-phosphati-
dylcholine to cholesterol. The chip surface was prepared for liposome
binding by sequential washes with 20 l of 1% octyl--D-glucopyrano-
side, 20l of 0.5% SDS, 10l of 1% octyl--D-glucopyranoside, and 10l
of 30% ethanol. Liposomes (1 mM, diluted in HBS-N) were injected until
the chip was saturated, giving a signal of approximately 8,000 response
units (RU). Once bound, the liposomes remained on the chip, and there
was no appreciable dissociation (no measurable off-rate). Purified soluble
gB(730t) (10 g/ml) was then injected for 240 s, followed by injection of
an antibody (100 g/ml for 240 s). Alternatively, 1 g of soluble gB was
incubated with 50 g of antibody in 50 l total of PBS for 1 h, and the
solution was then brought to 150 l with HBS-N buffer; this gB-Ab mix-
ture was then flowed across a liposome-covered chip for 240 s. After each
experiment, the surface preparation protocol was performed to remove
protein and liposomes from the chip, regenerating the surface to the RU
baseline. All injections were performed at a flow rate of 5 l/min.
RESULTS
FR1, which is located at the base of postfusion gB, is composed of
two structural domains (domains I and V, colored blue and red,
respectively, in Fig. 1A and B) and contains two fusion loops
(termed FL1 and FL2) per protomer. In our panel of anti-gB virus-
neutralizing MAbs, many of those with epitopes that map within
this broad region block cell-cell fusion and prevent gB from asso-
ciating with liposomes; however, the mechanism of action of
MAbs in each of these events is unknown (2, 14, 16, 20). To study
FR1 in more detail, we first needed to define more precisely the
epitopes that mapped to this region (14). Previously, we and oth-
ers identified 15 anti-gB MAbs that mapped to FR1, including
many with virus-neutralizing activity (14, 23–25, 40–42) (data not
shown). Among them, we chose four to study by EM: SS144 and
SS63, previously assigned to FR1; SS55, whose epitope was local-
ized within a large region corresponding to FR1 and FR2 (residues
98 to 472) via deletion mutants; and DL16, recently suggested to
be in FR1 (10). We also included MAbs C226 and SS10 as controls
and representatives for FR2 (located in the middle lobe of gB) and
FR3 (located in the crown), respectively. In each case, we purified
the Fab fragments (Fig. 2A), combined them with soluble
gB(730t), and purified the Fab-gB complex by gel filtration on a
Superdex 200 column. Figure 2B shows the separation of SS55
Fab-gB from free Fab. Fractions representing the complex were
pooled, concentrated, and used for EM studies.
Electron microscopy localizes important gB epitopes. As in
earlier studies (6, 10–13), when soluble gB is prepared for EM by
negative staining, the protein tends to orient preferentially with its
long axis lying in the plane of the support film (Fig. 3A and B). In
these side views, it appears as a three-lobed rod,18 nm long and
7 nm wide, whose ends are readily distinguishable, one having
the concave crown domain and the other occupied by the oval
base domain, which often has a patch of negative stain at its center
(Fig. 4A to C).
When Fabs are complexed with gB, one or two extra densities
are seen emanating laterally from gB (Fig. 3B and 4D to I); these
densities represent bound Fabs. The location of the SS10 epitope
(Fig. 4D) within the crown (FR3) agrees with the results of map-
FIG 2 (A) Coomassie stain of purified Fab from MAb SS55. (B) Fractionation of the gB1(730t)-SS55 Fab complex via size exclusion chromatography. Fractions
were analyzed on a denaturing SDS-PAGE gel and were visualized by silver staining. Fraction numbers are shown at the top; molecular size standards (in
kilodaltons) are indicated on the left.
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ping done with gB truncation constructs, which localized the
epitope of MAb SS10 to residues 640 to 670 (14). The binding of
MAb C226 was previously localized via a series of deletion mu-
tants to a region spanning aa 234 to 472 (14), which included
portions of both FR1 and FR2. However, a C226 mar mutation at
HSV-2 gB (gB2) residue 414 suggested that the C226 epitope was
closer to FR2 (the middle lobe of gB) than to FR1 (14). Indeed, the
EM data confirmed that C226 binds to the lateral knob-like struc-
ture in the central region of gB (Fig. 4E). Note that because C226
binds preferentially to gB2, we complexed its Fab with gB2. How-
ever, no difference in structure was seen between gB1(730t) and
gB2(724t) (compare Fig. 4C and E). The epitope of MAb SS55 was
also localized by use of deletion mutants, to a large region span-
ning residues 98 to 472 (14). However, in this case, the EM data
prove that the epitope is within the base of gB (i.e., FR1) (Fig. 4F).
Thus, the EM data clearly show that C226 and SS55 bind to dif-
ferent regions of gB. We previously mapped MAb SS144 within
two overlapping synthetic peptides (residues 697 to 725). Because
the N-terminal portion of this range is buried in gB(730t) (1), we
further narrowed the SS144 epitope to surface-exposed residues
715 to 725 (14). These data agree with the EM results that locate its
binding site near the base and to the side of gB, within FR1
(Fig. 4G).
MAb DL16 was of particular interest to us, because although it
is nonneutralizing, it is trimer specific (14). Most other conforma-
tion-dependent MAbs to gB recognize both the trimer and a fast-
er-migrating form (by SDS-PAGE) of the protein that corre-
sponds in apparent size to a monomer (14). The EM data clearly
show that DL16 binds to the base of gB within FR1 (Fig. 4H),
verifying the recent mapping data for this MAb using C-terminal
gB truncations (10). This observation was very interesting, since
DL16 competes with MAb H1817, which binds within the first 43
amino acids of the gB N terminus (FR4) (14) (Fig. 1C). FR4 was
not part of the gB ectodomain that was crystallized, and its loca-
tion within the postfusion trimer is unknown (Fig. 1B). FR4 resi-
dues may stretch downward (with respect to the solved structure),
thereby accounting for competition with DL16 (which was also
performed using a postfusion, soluble form of gB). Regardless, the
EM data clearly show that DL16 binds to the gB base, and there-
fore, its epitope is in FR1.
Finally, the SS63 epitope had been assigned to FR1 previously
gB-1
+
SS55
F
AVERAGES
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gB-1
+
SS144
G
gB-2
+
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E
gB-1
+
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H
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+
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I
gB-1
+
SS10
D
A B
MODELS
FIG 4 Two-dimensional class averaging of gB and Fab-bound gB. (A) Projec-
tion of a rotationally symmetrized gB model (PDB code 3NWF). (B) Projec-
tion of the gB model without imposed symmetry. (C) gB only. (D to I) Fab-
bound gB. The figure shows three representatives (left panels) and the 2D class
averages (rightmost panels) of each sample imaged. Bar, 20 nm.
FIG 3 Negative-stain electron microscopy of gB. Shown are negatively stained low-magnification fields of gB1(730t) (A) and gB1(730t)-SS55 Fab (B). Some
representative particles of each sample are circled. Bar, 50 nm.
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(14). However, EM analysis of SS63 Fab-gB definitively places the
epitope for this MAb in the crown of gB (FR3) (Fig. 4I). We have
accordingly reassigned SS63 to MAb group 4c (Fig. 1C). The orig-
inal mapping of the epitope of MAb SS63 relied solely on peptide
binding data and did not take into account the antibody compe-
tition data. That said, there is at least one stretch of amino acids
within the crown (aa 98 to 115) that has a fair amount of sequence
identity with the peptide to which SS63 bound.
In summary, the EM analyses of Fab-gB complexes provided
compelling grounds for assigning MAb epitopes to FR of gB. For
the remainder of this study, we concentrate on the following anti-
FR1 antibodies with epitopes in domains I and V: the neutralizers
SS55 and SS144 and the nonneutralizer DL16.
marmutants furthermap the SS55 epitope.We had proposed
that the neutralizing mechanisms of SS55 and SS144 are based on
obstructing the FL-lipid interaction (16). Yet the EM data show
that SS55 and SS144 Fabs bind on the “side” of the base (Fig. 4F
and G) and not at its apex, where the FLs are located (Fig. 1A).
SS144 was previously mapped via overlapping peptides and sur-
face availability to a linear stretch of residues in FR1 (residues 715
to 725) (14). To further define the discontinuous SS55 epitope, we
followed up on the EM data by using the MAb to select for mar
mutant viruses (34). Two separate mar viruses were obtained,
both of which infected Vero cells in the presence or absence of
SS55 (data not shown). Sequencing of the gB open reading frames
from these mutants revealed two different amino acid changes. In
one mutant, there was an A-to-T change at residue 203; in the
other, an R-to-Q change at residue 335. Although quite far apart
in the linear protein sequence, these two amino acids lie close to
each other in domain I of the postfusion structure (Fig. 5A) and fit
well with the position of SS55 Fab binding to gB (Fig. 4F).
We cloned both of these gB mutants into mammalian expres-
sion plasmids. Additionally, since residue A203 is located next to a
two-turn -helix (Fig. 5A), we wondered if the neighboring turn
of the helix would also be within the SS55 epitope. Therefore, we
mutated Asp199 to Ala in a cell extract containing full-length gB
(which likely comprises both pre- and postfusion forms). We used
ELISA to test MAb binding by each mutated form of gB by first
capturing the proteins with an antibody to the gB cytoplasmic tail
and then determining how well each MAb bound to gB-A203T,
gB-R335Q, and gB-D199A, after normalizing the data to that for
binding to WT gB (Fig. 5B). As expected, these three mutants
bound to SS10 and C226; however, none of them reacted with
SS55. We conclude that residues D199, A203, and R335 are all
within the SS55 epitope in structural domain I. Remarkably,
SS144 failed to bind to any of the SS55 mar proteins. Although the
two epitopes are in different structural domains (Fig. 1A and 5A),
changes to the SS55 epitope clearly affect the SS144 epitope. In-
terestingly, anti-FR1 MAb DL16 bound to all three mar proteins
(Fig. 5B), indicating that not all MAbs that bind to the gB base are
affected by the SS55 mar mutants.
Anti-FR1 IgGs and Fabs inhibit gB-liposome association. To
gain insight into how anti-FR1 antibodies affect gB function, we
next tested their abilities to block the binding of gB(730t) to lipid
by using a biosensor-based liposome binding assay (27). This
postfusion form of gB associates with liposomes in vitro via the FLs
(13), and this association is altered by either (i) mutations to res-
idues in the FLs (15, 16), (ii) the presence of the membrane-prox-
imal region (MPR; residues 731 to 773) (27), or (iii) blocking by
IgG from anti-FR1 MAbs, such as SS55 or SS144 (16). Another
anti-FR1 MAb, 2c, has been shown to neutralize virus via IgG
cross-linking, since Fabs generated from this MAb did not inhibit
virus infection (43). We therefore asked how the individual Fabs
for SS55 and SS144 would behave in liposome binding and virus
neutralization assays.
Previously, we used a liposome flotation assay to demonstrate
inhibition of the gB-liposome association by IgGs (16). We
adapted our method of determining the binding of gB to lipo-
somes via biosensor analysis (27) to now measure the association
of gB with liposomes in the presence of anti-gB IgGs or Fabs. In
this assay, liposomes were immobilized on an L1 biosensor chip
surface, and gB(730t) was flowed across the chip. As expected, we
observed an increase in response units (RU), indicative of the
binding of protein to the liposomes (Fig. 6A, black lines). As a
negative control for blocking, we preincubated gB with the anti-
FR2 MAb C226. The presence of C226 IgG or Fabs did not block
the binding of gB to liposomes (Fig. 6); in fact, the percentage of
liposome-bound gB increased when C226 IgG was present. This
observation is likely due to the increased mass of gB-IgG com-
FIG 5 Identification of SS55 mar mutants. (A) Structure of FR1 from a gB
monomer, based on the work of Stampfer et al. (6), with resolution of the loop
between A328 and A338 at a low pH. The epitope of MAb SS144 is shown in
red, and the fusion loops are shown in pink (FL1) and cyan (FL2). SS55 mar
residues A203, R335, and D199 are highlighted in blue. Blue dots indicate the
positions of A203 and R335 on the ribbon. (B) Full-length gB from transfected
cell extracts was captured via PAb R242 (against the gB cytoplasmic tail) and
was probed with anti-gB MAbs in an ELISA. Results of a representative exper-
iment are shown. The percentage of WT absorbance was calculated as follows:
(absorbance of test sample at 405 nm/absorbance of WT sample) 100.
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plexes. With the nonneutralizing MAb DL16, both the IgG and
Fabs partially blocked the association of gB with liposomes (Fig.
6). This was understandable in light of the location where DL16
binds (Fig. 4H). In contrast, when gB was preincubated with either
SS55 or SS144 IgGs, the complexed gB bound poorly to liposomes;
gB-liposome association was reduced to a level 20% that of WT gB
(Fig. 6B). When gB was complexed with either SS55 or SS144 Fabs,
binding was also reduced to25%. Since the EM data suggest that
these MAbs do not bind to the FLs, blocking (especially by the
Fabs) could be caused by an indirect effect, such as a structural
alteration upon MAb binding that, in turn, affects FL position.
Alternatively, the blocking could be due to steric hindrance, even
by the smaller Fabs.
FR1 neutralizing epitopes remain accessible on lipid-bound
gB. Following up on these two possibilities, we asked if steric hin-
drance plays a role in the abilities of SS55 and SS144 to block the
binding of gB to liposomes. If so, we reasoned that their epitopes
should be inaccessible to antibody when gB was prebound to li-
posomes. To address this, we coated an L1 chip with liposomes
and then injected gB(730t); gB binding to liposomes was seen as
an increase in RU (Fig. 7). Next, IgGs were sequentially flowed
across the chip surface. In the first experiment of this series (Fig.
7A), we injected first MAb SS55, then SS144, and finally SS10.
SS55 was still able to bind, as evidenced by the increase in RU.
SS144 gave no additional signal, since it was blocked from binding
by SS55 (as seen in our previous competition studies using gB
without liposomes [14]). As a control, the anti-FR3 MAb SS10,
which does not compete with either SS55 or SS144, was injected
last, and an increase in RU was seen, indicating that this epitope
was still available.
Next, we reversed the order of addition of SS144 and SS55. In
this case, MAb SS144 bound to gB-liposome complexes and con-
sequently blocked the binding of SS55 (Fig. 7B). Finally, we per-
formed the same experiment with DL16 and found that, like the
other anti-FR1 MAbs, it also bound to liposome-associated gB
(Fig. 7C). Thus, although SS55 and SS144 prevent soluble gB from
interacting with lipids, they are still able to bind to gB when the
protein is bound to lipid membranes. Notably, cryoelectron to-
mography shows that the interaction of the base of soluble gB with
liposomes is limited to the outer leaflet of the lipid bilayer and that
the FLs associate with liposomes but are not inserted (13), thus
leaving space for each of these anti-FR1 MAbs to bind. Taking
these results together with our previous data, we suggest that the
FR1 neutralizing antibodies bind at sites distinct from the FLs to
inhibit the association of gB with lipids, possibly through an alter-
ation of FR1 structure and not through steric hindrance.
SS55 and SS144 Fabs neutralize better than their respective
IgGs. Our liposome experiments were done using gB(730t), a sol-
FIG 6 Antibodies against neutralizing epitopes in FR1 block gB-liposome
binding. (A) Fifty micrograms of each antibody (IgG or Fab) was incubated
with 1 g of purified, soluble gB(730t) for 1 h, and the complex was then
flowed across liposomes bound to an L1 biosensor chip. Solid black curves
represent the RU of gB binding to liposomes; dashed curves represent those for
gB plus Fab (right); and gray curves represent those for gB plus IgG (left). The
response from Fab or IgG flowing across liposomes only (no gB) was sub-
tracted from the curves. (B) Bar graph representing the percentage of gB
bound to liposomes for each sample. The percentage of gB bound was calcu-
lated based on maximal binding after 240 s as follows: (RU of test sample [after
injection of gB-Ab]/RU of WT) 100. Error bars indicate standard errors for
at least two experiments.
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uble postfusion form of gB. To understand how SS55 and SS144
function to block virus entry, we revisited virus neutralization.
Our thinking was that if IgG cross-linking plays a role in the func-
tion of these antibodies, then neutralization by the full IgG would
be better than that seen for the Fab. In order to easily compare IgG
with Fab, the IgG concentrations in Fig. 8 were corrected for the
amount of Fab by assuming that 1 g of Fab equals 1.5 g of IgG.
As a control, we tested both the IgG and the Fab of anti-FR2
MAb C226. In this case, both forms of the antibody neutralized
virus infectivity with the same efficiency (Fig. 8A). As with C226, a
number of other reported cases have shown that Fab activity is
either the same as or less than that of its parental IgG (43–46). As
expected from previous studies (14), the IgGs of MAbs SS55 and
SS144 neutralized virus well; each inactivated the infectivity of
50% of the input virus at concentrations between 5 and 20 g/ml
(Fig. 8B and C, filled diamonds). In contrast, the Fabs for both
SS55 and SS144 showed a marked improvement in neutralization
activity. The 50% neutralization point for each Fab was0.6 g/
ml, an 8- to 30-fold increase in potency over that of the parental
IgGs (Fig. 8B and C, open squares). To our knowledge, this
marked enhancement of neutralization by a Fab is unique. We
believe that this improvement in neutralization reflects an im-
proved ability of these two Fabs to reach their particular epitopes.
Generation of antibodies directed against the fusion loops.
Because none of the anti-FR1 MAbs in our collection bind directly
to the FLs, we decided to prepare antibodies to the FLs themselves.
To do this, we hyperimmunized rabbits with a peptide spanning
FL1 (residues 167 to 186) or FL2 (residues 252 to 271) (Fig. 9A).
Anti-FL1 failed to react with gB(730t) by Western blotting (data
not shown) and was not studied further. In contrast, anti-FL2
bound denatured, but not native, gB (Fig. 9B, left). To enhance the
reactivity of anti-FL2, we enriched for gB-specific IgGs by passing
the total IgG for anti-FL2 over a gB2(724t) antigen-sorbent col-
umn (where soluble gB is covalently linked to Sepharose 4B). Col-
umn-purified antibody, termed anti-FL2p IgG (representing
0.5% of the total IgG), readily bound both native and denatured
gB(730t) (Fig. 9B, right). Surprisingly, anti-FL2p also bound na-
tive gB(773t), a longer form that contains the structurally unre-
solved MPR but is likely also a postfusion form of gB (13, 27). The
FLs were originally thought to be obscured (and perhaps inacces-
sible to antibody) in gB(773t), since this form exhibits reduced
liposome binding (27).
To ensure that anti-FL2p IgG was specific for the FL region, we
performed ELISA with overlapping 20-mer peptides that spanned
the two FLs. Anti-FL2p IgG reacted with two peptides corre-
sponding to FL2 (Fig. 9C) but also reacted with two peptides cor-
responding to FL1. The latter result is not surprising, since the two
FLs share some sequence identity (Fig. 9A, identical residues un-
derlined). Therefore, it is possible that some of the attributes of
anti-FL2p are due to its ability to bind both FL1 and FL2, i.e., it
binds a fusion region. Therefore, we will consider this antibody to
react with both loops in the context of gB itself.
Anti-FL2p can bind lipid-bound gB and neutralize virus in-
fectivity.By the same method used for Fig. 7, we used anti-FL2p to
test the accessibility of the antigenic sites on liposome-bound sol-
uble gB (Fig. 10A). To our surprise, like the anti-FR1 MAbs, anti-
FL2p readily bound to lipid-associated gB(730t). We conclude
that a portion of FL2 and possibly the FL1 of gB(730t) is exposed
even when the protein is bound to lipid.
Since the fusion region is accessible when gB is associated with
FIG 7 Liposome binding assay and biosensor analysis. Liposomes are injected
into the L1 chip to saturation (8,000 RU) (not shown), and soluble gB(730t)
is then injected at 5 l/min for 240 s, followed by the indicated antibody (240
s); binding to liposomes is measured as an increase in RU. There is some
day-to-day variability in the RU of gB captured on the liposomes (y axis val-
ues), because different batches of liposomes and different preparations of gB
were used. However, the concentrations of liposomes and gB were always held
constant, and the test samples were always compared to a control (IgG or Fab
flowed across liposomes only) on the same day. The beginning of each injec-
tion is indicated with an arrow, and arrowheads along the x axis show where
each injection was stopped. (A and B) Competition for binding to gB between
MAbs SS55 and SS144. SS10, SS55, and SS144 were injected at a concentration
of 75g/ml. (C) DL16 was injected at a concentration of 50g/ml. The double
slash in the x axis indicates a pause before the injection of DL16.
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liposomes, we next asked if it would also be accessible on gB in the
context of virus and, if so, whether anti-FL2p IgG could neutralize
virus. One might expect that anti-FL2p would be either (i) non-
neutralizing, because the FLs are inaccessible in prefusion gB on
the virus, or (ii) neutralizing, because of direct interference with
FIG 8 Virus neutralization. Serial dilutions of IgG or Fab of each MAb were
mixed with HSV-1 KOS for 1 h at 37°C and were then added to Vero cells.
Plaques were visualized 24 h later by the black plaque assay. Data are plotted as
percentages of the result for the no-antibody sample. Dashed lines highlight
the concentrations for 50% neutralization of virus. The IgG concentrations
used were corrected for the amount of Fab by assuming that 1g of Fab equals
1.5 g of IgG.
FIG 9 (A) gB peptides used to generate anti-FL1 and anti-FL2 PAbs. The
sequence of each FL is identical for gB1 and gB2 (1). The numbers of the first
and last amino acids of each peptide are shown. Residues that are accessible on
the surface of the gB trimer are shown in boldface (1), and amino acids iden-
tical in FL1 and FL2 are underlined. (B) Western blots of purified, soluble gB
probed with anti-FL2 or anti-FL2p. Molecular size standards (in kilodaltons)
are shown on the left. T, trimer; M, monomer; N, native gel; D, denaturing gel.
(C) ELISA using anti-FL2p against overlapping gB2 peptides that encompass
the fusion domain. Each gB2 peptide (x axis) is 20 residues long and has a
10-residue overlap with peptides on either side. Peptides that contain FL1 and
FL2 sequences are indicated.
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the gB-lipid binding step of fusion. To answer these questions, we
tested anti-FL2p in our neutralization assay (Fig. 10B). Anti-FL2p
IgG neutralized virus in a dose-dependent manner (50% neutral-
ization at 40 g/ml). In contrast, the total anti-FL2 IgG (not en-
riched for gB-specific IgGs) had no effect on virus infectivity. The
fact that a PAb generated against the FL2 peptide neutralized virus
suggests that the FLs are accessible to antibody on gB that is within
the virus envelope at the time of infection.
Taken together, our data uncover how different antibodies
with epitopes in FR1 neutralize virus infection. MAbs such as
SS55 and SS144 do not bind the FLs directly but may instead
alter them upon binding, thereby impairing gB-lipid associa-
tion and membrane fusion. Lastly, a PAb generated against FL2
neutralizes virus, suggesting that the FLs are a viable target for
antibody.
DISCUSSION
Our purpose here was to dissect the properties of gB functional
region 1 (FR1), the portion of gB that interacts with lipid, houses
the fusion domain, and contains the antigenic sites for numerous
neutralizing antibodies.
Comments about the Fab/gB EM study. We used EM to visu-
alize the actual location of Fabs for antibodies binding to three of
the four FR and to resolve ambiguities in our earlier mapping
efforts (Fig. 11). These studies confirmed the locations of four
antibodies chosen as representatives (SS10 in the crown of gB
[FR3], C226 in the middle lobe [FR2], and SS55 and SS144 in the
base [FR1]). Additionally, we determined the general locations of
two other antibodies, SS63 and DL16. The SS63 epitope was orig-
inally assigned to FR1 (14), but EM clearly shows that it binds to
the gB crown at the other end of the molecule (FR3). Because we
use the nonneutralizing MAb DL16 extensively for gB purifica-
tion, and because a number of other laboratories have taken ad-
vantage of its trimer-specific property (6, 10, 47–49), it was im-
portant to locate its epitope. While Vitu et al. (10) have suggested
that DL16 binds to FR1 (residues 678 to 730 of structural domain
V) based on its inability to bind C-terminal gB truncation con-
structs, our competition data showed that it competes with MAb
H1817, known to bind within FR4 (residues 31 to 43) (Fig. 1C)
(14). Since this region of gB is not resolved in the crystal structure,
we originally thought that DL16 might bind near the N terminus,
expected to be near the crown. Rather, our current EM data show
DL16 binding to the base of gB (FR1). Taken together, the com-
petition and EM data for DL16 suggest that perhaps FR4 stretches
downward toward the gB base (FR1) when gB is in the postfusion
form. In fact, when one compares the projections of the solved
atomic structure (Fig. 4A and B) with the 2D class averages of
negatively stained gB (Fig. 4C, right), it becomes apparent that the
crown and the middle lobe are larger than the atomic model sug-
gests. This indicates that the N terminus likely extends toward the
base of the protein, interacting with domains IV, III, and II, and
FIG 10 (A) Binding of anti-FL2p to liposome-associated gB was performed
using biosensor analysis as described in the legend to Fig. 7. (B) Neutralization
assays were performed as for Fig. 8, except that HSV-2 (333) was used. Filled
circles, total IgG; open circles, gB-specific IgG. Dashed lines highlight the IgG
concentrations for 50% neutralization of virus.
FIG 11 Epitopes of anti-gB MAbs displayed on a surface representation of the
gB trimer. EMs showing gB-Fab complexes for each MAb are also shown, and
arrows lead to their epitopes. Epitopes are colored according to the structural
domain in which they are located, as in Fig. 1: SS10 (residues 640 to 670),
orange; C226 (residue 419), green; SS55 (residues 199, 203, and 335), blue;
DL16, red (circled); SS144 (residues 715 to 725), red. Epitope mapping data for
MAbs SS10, C226, SS144, and DL16 have been published previously (10, 14).
The epitope for MAb SS63 is localized to the crown via EM of gB-Fab com-
plexes, and its residues are unknown (dashed orange circle).
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positioning FR4 (residues 31 to 86) more distant from the crown
than originally expected, conclusions differing somewhat from
those reached using cryo-EM (13). Thus, this approach has solid-
ified and extended our immunological/biochemical analysis.
gB(730t) is a trimer (1) and presumably presents three copies
of each epitope at 120° intervals around its axis. However, we
rarely saw clear-cut examples of decoration with three Fabs (Fig.
3B and 4). We attribute this to the fact that specimens tend to
flatten onto the support film when air dried in a negative stain. As
a result, the third Fab could become detached or perhaps protrude
along the line of sight, out of the stain layer. It is also possible that
the binding of two Fabs might preclude the binding of a third, due
to an induced structural change. Notably, there is a precedent for
nonstoichiometric Fab binding on trimeric proteins: the long tail-
fibers of T-even bacteriophages, which, when decorated with spe-
cific Fabs and imaged by negative staining, show one Fab protrud-
ing on either side (50) despite the fact that they are trimeric, as
established by scanning transmission EM (STEM) mass measure-
ments (51) and crystal structure analysis (52).
How do SS55 and SS144 block gB binding to liposomes?
Originally, we mapped SS144 to structural domain V with syn-
thetic peptides, since it binds a linear epitope, and this assignment
is in agreement with the EM results presented here. On the other
hand, SS55 binds to a conformation- and trimer-specific epitope
that our EM data, in combination with the results from proteolytic
fragments, localize to structural domain I. Yet these two antibod-
ies compete for binding to the postfusion soluble form of gB
[gB(730t)] (14). Since both MAbs bind to FR1 (albeit to different
structural domains), one explanation for the observed competi-
tion is that the binding of one MAb blocks the other by steric
hindrance. However, DL16 also binds within the base and does
not hinder the binding of either SS55 or SS144 (14).
Both SS55 and SS144 (and their respective Fabs) block the
binding of gB to liposomes, although they both still bind after gB
is already liposome bound. We argue that these two MAbs influ-
ence conformational changes in gB that alter its ability to bind to
liposomes. Much like the handles of scissors controlling the blades
through a pivot point, the binding of SS55 or SS144 to its epitope
could have an allosteric effect on the FLs. Such effects might also
explain why SS55 mar mutants within domain I also fail to bind
SS144 (Fig. 5B). The EM data show that when SS55 and SS144
bind to soluble gB(730t), the Fabs are angled slightly downward,
toward the base (Fig. 4F and G). One could also speculate that the
formation of this structure does not allow the FLs to get close
enough to the lipid membrane to associate with it. It is also possi-
ble that liposome-bound gB binds SS55 and SS144 because only a
subset of the FLs of the trimer are inserted into the liposome, while
the remainder are exposed for antibody binding. This possibility is
consistent with the EM data showing that many gB molecules have
fewer than three Fabs binding to gB at once.
The EM data also suggest that although DL16 binds FR1, its
binding differs from the binding of SS55 and SS144 (Fig. 4). When
DL16 Fabs bind, they are positioned outward and away from the
gB-lipid binding interface (Fig. 4H). Moreover, DL16 binds to
both SS55 mar mutants, further evidence that it is binding to a
different portion of FR1 than SS55 and SS144 (Fig. 5B). These data
could explain why DL16, though binding within FR1, only par-
tially blocks gB-liposome association.
In a previous study (13), we noted that when gB(730t) associ-
ates with liposomes, there are lateral projections of the base of the
protein that form an extended surface, which we termed a “fusion
patch.” We further suggested that the charged and hydrophobic
residues of such a patch could anchor the protein on the mem-
brane by interacting with the charged lipid head groups and hy-
drophilic carbon tails, respectively. We now propose that SS55
and SS144 prevent the formation of the fusion patch or the inter-
action of one or both FLs with the outer leaflet of a lipid bilayer.
Neutralizing properties of SS55, SS144, and C226. It is in-
triguing that the Fabs for SS55 and SS144 neutralize virus signifi-
cantly better than their parental IgGs, given that the majority of
Fabs have equal or weaker neutralizing activity (43–46). A previ-
ous report regarding neutralizing anti-gB MAb 2c, whose epitope
also maps to FR1 (43, 53), showed that this MAb required 94-fold
more Fab than IgG to reduce virus infection to the same extent
(43). The antiviral activity of MAb 2c is a consequence of gB cross-
linking; the addition of secondary antibodies to the Fab restores its
neutralization activity to near-IgG levels. We suggest that the
epitopes of SS55 and SS144 are more accessible to Fabs than to
full-sized IgG. This is not the case for C226 (FR2), whose Fab
neutralizes virus to the same extent as its parental IgG; perhaps its
epitope is equally accessible to both. It is important to remember
that the gB crystal structure depicts the postfusion form of gB;
these epitopes may be presented differently on prefusion gB (7,
17).
Anantibody toFL2provides further insight into thewayFR1
functions. In a variety of viruses, antibodies raised to fusion pep-
tides and loops have neutralizing properties, and the prevailing
thought is that these loops and peptides are hidden until the fusion
protein goes from a pre- to a postfusion state (54–59). Yet an
antibody against an FL2 peptide was neutralizing for both HSV-1
(data not shown) and HSV-2, implying that some portion of the
FLs or the surrounding residues are exposed on full-length gB
when it is in the viral membrane. These data suggest that HSV gB
is akin to parainfluenza virus F and VSV G, which have partially
exposed fusion peptides/loops in their prefusion forms (60, 61).
Furthermore, anti-FL2p binds to gB(730t) when the latter is
bound to liposomes, indicating that the extended surface in the
fusion patch does not prevent the FLs from contacting antibodies.
Additionally, FL2 is known to change conformation upon expo-
sure to a low pH (and presumably during endosomal entry),
adopting an “outward” conformation that moves it away from
FL1 (6). It is possible that at a neutral pH, FL2 (and perhaps FL1)
adopts a similar conformation upon exposure to lipid in order to
achieve membrane association. In the future, we plan to test anti-
FL2p against our panel of FL mutants to try to pinpoint its epitope
further.
In summary, we have examined the interaction of a truncated
postfusion form of gB with Fabs to localize epitopes and with
artificial membranes (liposomes), and then we have tried to ex-
trapolate those findings to a “real” situation, i.e., virus-cell fusion
and virus neutralization. However, the nature of the prefusion
form of gB remains elusive. Assuming that these in vitro events can
be transposed onto actual fusion events, at which step(s) in the
prefusion-to-postfusion structural cascade do FR1 neutralizing
antibodies block the gB-lipid interaction? We envision that they
should block just before or at the time when the FLs interact with
a cell membrane to begin infection. We further propose that these
antibodies alter the interaction of the fusion domain with the
outer leaflet of the host membrane. Our data suggest that in viri-
ons, the FLs are likely exposed to the environment prior to the
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onset of fusion, i.e., when gB is in a prefusion or intermediate
form. Clearly, more needs to be uncovered about the structure of
the prefusion form(s) of gB and the positions of the FLs in that
structure. In future studies, we plan to use anti-FR1 Fabs, includ-
ing anti-FL2p or a monoclonal antibody to the FL2 peptide, to
attempt to trap a prefusion form of gB, as has been done for respi-
ratory syncytial virus F in complex with a Fab for a neutralizing
MAb (59).
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